| Autor: |
Ge DW; Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. leiyangspine@163.com., Wang WW, Chen HT, Yang L, Cao XJ |
| Jazyk: |
angličtina |
| Zdroj: |
European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2017 Nov; Vol. 21 (21), pp. 4784-4789. |
| Abstrakt: |
Osteoporosis (OP) is a kind of disease with a 25% incidence, characterized by the bone mass loss, bone microstructure damage, increased bone fragility, and easy fracture. miRNA plays an important regulatory role in the process of bone remodeling, especially in the regulation of differentiation and function of osteoblasts and osteoclasts, and the development and progression of OP and other bone diseases. In the future, it is expected to delay the bone loss and promote the bone remodeling via the overexpression or inhibition of specific miRNAs in specific tissues, thereby treating OP. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
